Effimune S.A.S. is a biotechnology company conducting research and development of innovative drug candidates for transplantation and immune-mediated diseases. The company specializes in the development of first-in-class biological drug candidates targeting cells of the immune system to restore the balance between effector and regulatory mechanisms. Three product candidates are currently in development, one of them in collaboration with our partners Janssen Biotech.
Looking for a particular Effimune employee's phone or email?
The Effimune annual revenue was $5 million in 2026.
Marc Moguilewsky is the VP Business Development of Effimune.
1 people are employed at Effimune.
Effimune is based in Nantes, Pays de la Loire.
The NAICS codes for Effimune are [541713, 541, 5417, 54171, 54].
The SIC codes for Effimune are [87, 873].